Stay updated with breaking news from Healio Coverage. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has set a new target action date for ARS Pharmaceuticals’ neffy epinephrine nasal spray, which is designed to treat anaphylaxis and other type 1 allergic reactions without a needle or injection. The new action date has been extended to Sept. 19.
Out of more than 20,000 dietary supplements, only one had sufficient nutrients in required doses that pregnant patients need, according to a study recently published in The American Journal of Clinical Nutrition. Researchers found that the supplement that contained target doses for six important nutrients was more expensive and required more tablets per serving. It was the top story in
A 0.5 mg dose of colchicine, a drug commonly used for conditions such as gout, was recently approved by the FDA to prevent cardiovascular events in patients with residual inflammatory risk.It is the first anti-inflammatory agent to be approved as an atheroprotective CV treatment, according to a press release from the manufacturer, and is expected to be available later this year. News of the
Although the number of alpha-gal syndrome tests increased in Tennessee from 2013 to 2022, the proportion of confirmed cases remained stable, recent data show. Researchers discussed how increased awareness has played a role in increased testing. They said their findings indicate that providers are correctly homing in on key features of alpha-gal syndrome. It was the top story in allergy/asthma
A recent study found that undergoing a hysterectomy before the age of 50 years may increase the risk for CVD, specifically stroke. “Examining the use of hysterectomy at a younger age and women’s risk of CVD is important since it is a commonly performed gynecologic procedure with well-documented benefits in relieving symptoms and improving quality of life,” Jin-Sung Yuk, MD, PhD,